Table 2.
Risk factor management at follow-up
| CKD-1 | CKD-2 | CKD-3 | CKD4–5 | p value | |
|---|---|---|---|---|---|
| Medications after PCI | |||||
| Statin | 15 (84) | 40 (95) | 26 (90) | 21 (85) | 0.24 |
| (Continue statin group: CS) | 4 (22) | 14 (33) | 10 (34) | 11 (46) | 0.45 |
| (Initiate statin group: IS) | 11 (61) | 26 (62) | 16 (55) | 10 (42) | 0.79 |
| β-blocker | 8 (44) | 12 (29) | 18 (62) | 12 (50) | 0.04 |
| DAPT | 60 (100) | 33 (100) | 20 (100) | 20 (100) | – |
| ACE-I/ARB | 13 (72) | 25 (60) | 20 (69) | 17 (71) | 0.7 |
| Clinical data at follow-up | |||||
| LDL cholesterol (mg/dl) | 96 ± 19 | 87 ± 26 | 81 ± 18 | 87 ± 34 | 0.3 |
| HDL cholesterol (mg/dl) | 54 ± 11 | 55 ± 14 | 55 ± 15 | 47 ± 13 | 0.1 |
| HbA1c (%) | 6.3 ± 1.2 | 6.2 ± 1.0 | 6.2 ± 0.7 | 6.9 ± 1.3 | 0.03 |
| CRP (mg/dl) | 0.2 ± 0.2 | 0.2 ± 0.9 | 0.1 ± 0.1 | 0.3 ± 0.4 | 0.6 |
| SBP (mmHg) | 120 ± 15 | 119 ± 13 | 130 ± 23 | 133 ± 20 | 0.008 |
| DBP (mmHg) | 72 ± 15 | 67 ± 10 | 73 ± 15 | 71 ± 12 | 0.3 |
| Change from baseline | |||||
| LDL cholesterol (mg/dl) | −17 ± 37 | −19 ± 33 | −20 ± 28 | −15 ± 46 | 0.9 |
| HDL cholesterol (mg/dl) | +2 ± 7 | +1 ± 10 | 0 ± 9 | 0 ± 11 | 0.9 |
| HbA1c (%) | 0 ± 0.4 | 0 ± 0.8 | 0 ± 0.7 | +0.4 ± 0.8 | 0.06 |
| CRP (mg/dl) | −0.4 ± 0.7 | −0.4 ± 1.5 | −0.2 ± 0.9 | −0.3 ± 1.6 | 0.9 |
| SBP (mmHg) | −16 ± 23 | −10 ± 22 | −3 ± 24 | −8 ± 32 | 0.3 |
| DBP (mmHg) | −12 ± 15 | −5 ± 14 | −1 ± 13 | −4 ± 16 | 0.1 |
| Achievement ratio of target control level at follow-up | |||||
| LDL cholesterol <100 mg/dl | 10 (55) | 31 (74) | 24 (83) | 16 (67) | 0.2 |
| HDL cholesterol >40 mg/dl | 17 (94) | 37 (88) | 22 (76) | 17 (71) | 0.1 |
| HbA1c <7.0 % | 15 (83) | 39 (93) | 24 (83) | 12 (50) | 0.03 |
| SBP <140 mmHg | 16 (89) | 40 (95) | 22 (76) | 17 (71) | 0.03 |
| DBP <80 mmHg | 12 (67) | 36 (86) | 21 (72) | 20 (83) | 0.3 |
Data are expressed as mean ± SD or number (%)
Continue statin group: CS, patients with statin treatment have already initiated before PCI
Initiate statin group: IS, patients with statin treatment initiated after PCI
DAPT dual antiplatelet therapy, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker